Strategies to overcome drug resistance using SHP2 inhibitors

作     者：Meng Liu Shan Gao Reham M.Elhassan Xuben Hou Hao Fang Meng Liu;Shan Gao;Reham M.Elhassan;Xuben Hou;Hao Fang

作者机构：School of Pharmaceutical SciencesCheeloo College of MedicineShandong UniversityJinan 250012China 

出 版 物：《Acta Pharmaceutica Sinica B》 (药学学报（英文版）)

年 卷 期：2021年第11卷第12期

页      面：3908-3924页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 1006[医学-中西医结合] 1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100706[医学-药理学] 1001[医学-基础医学(可授医学、理学学位)] 100602[医学-中西医结合临床] 10[医学] 

基　　金：supported by National Natural Science Foundation of China(Grant No.81874288,92053105 and 82003590) Natural Science Foundation of Shandong Province(ZR2020QH342,China) the Young Scholars Program of Shandong University(China) 

主　　题：SHP2 inhibitor Allosteric inhibitor Anti-cancer Drug resistance 

摘      要：Encoded by PTPN11,the SHP2(Src homology-2 domain-containing protein tyrosine phosphatase-2)is widely recognized as a carcinogenic *** a promising anti-cancer drug target,SHP2 regulates many signaling pathways such as RAS-RAF-ERK,PI3 K-AKT and ***,SHP2 plays a significant role in regulating immune cell function in the tumor ***,five SHP2 allosteric inhibitors have been recruited in clinical studies for the treatment of *** recently,studies have proved the therapeutic potential of SHP2 inhibitor in overcoming drug resistance of kinase inhibitors and programmed cell death-1(PD-1)***,we review the structure,function and small molecular inhibitors of SHP2,and highlight recent progress in overcoming drug resistance using SHP2 *** hope this review would facilitate the future clinical development of SHP2 inhibitors.